Haleon plc (NYSE:HLN) Shares Purchased by Sei Investments Co.

Sei Investments Co. lifted its stake in Haleon plc (NYSE:HLN) by 2.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 802,507 shares of the company’s stock after buying an additional 21,418 shares during the period. Sei Investments Co.’s holdings in Haleon were worth $6,629,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Cultivar Capital Inc. purchased a new stake in Haleon during the 2nd quarter worth $40,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Haleon during the first quarter worth about $43,000. GAMMA Investing LLC lifted its stake in shares of Haleon by 151.3% in the first quarter. GAMMA Investing LLC now owns 6,106 shares of the company’s stock worth $52,000 after acquiring an additional 3,676 shares in the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Haleon by 29.8% in the first quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock worth $53,000 after acquiring an additional 1,421 shares in the last quarter. Finally, Hexagon Capital Partners LLC boosted its holdings in Haleon by 66.6% in the second quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after purchasing an additional 2,677 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Down 0.7 %

NYSE:HLN opened at $10.59 on Tuesday. The company has a market cap of $48.36 billion, a PE ratio of 35.30, a P/E/G ratio of 3.12 and a beta of 0.26. The business’s 50 day moving average is $9.97 and its two-hundred day moving average is $8.97. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 52 week low of $7.70 and a 52 week high of $10.80.

Haleon (NYSE:HLN) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The firm had revenue of $3.50 billion for the quarter, compared to the consensus estimate of $3.55 billion. During the same quarter last year, the business earned $0.08 earnings per share. On average, analysts predict that Haleon plc will post 0.47 EPS for the current year.

Haleon Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Investors of record on Friday, August 16th were given a dividend of $0.0514 per share. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend was Friday, August 16th. Haleon’s dividend payout ratio is presently 33.33%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HLN. Morgan Stanley upped their target price on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. Berenberg Bank started coverage on shares of Haleon in a report on Tuesday, August 6th. They issued a “buy” rating on the stock. Finally, The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.